Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.

Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.

Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.

Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.

Abstract: A rotary powder compression machine with a horizontal turntable for compressing powder placed into a compression bore between an upper and a lower compression rods. An ultrasonic sensor monitors the amount of powder deposited upstream of the open feed shoe in the rotation direction of the turn-table.

Abstract: A composite measure of varying capacity, composed of supplying-aperture of straight cylinder and an inside measure telescopically inserted into the aperture and having a hollow of frusto-conical section, is employed in order to improve accommodation of the known conventional capacity type rotary powder filling machine, to powder of varying bulk density.A turntable which receives the supplying-aperture, superimposes over another turntable which holds the inside measure, and the distance between the both, is adjustable during the operation in accordance with the variance in the bulk density. The height of the container transferring path is also adjustable simultaneously with that of the second turntable.Spouting of compressed-air through an annular nozzle the diameter of which approximates to that of the aperture as a flow parallel to their inside wall is effected to blow off remaining powder in the measure and clean the same when the nozzle is disposed on the aperture.